EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Androgenic Alopecia - Pipeline Review, H2 2016

  • ID: 4030247
  • Report
  • December 2016
  • 70 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Aclaris Therapeutics Inc
  • Allergan Plc
  • Almirall SA
  • BiologicsMD Inc
  • Histogen Inc
  • Samumed LLC
  • MORE
Androgenic Alopecia - Pipeline Review, H2 2016

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Androgenic Alopecia - Pipeline Review, H2 2016, provides an overview of the Androgenic Alopecia (Dermatology) pipeline landscape.

Androgeneic alopecia is a genetically determined disorder characterized by the gradual conversion of terminal hairs into indeterminate, and finally into vellus, hairs. It is an extremely common disease that affects men and women. Predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Androgenic Alopecia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Androgenic Alopecia (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Androgenic Alopecia (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Androgenic Alopecia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 8, 4 and 1 respectively.

Androgenic Alopecia (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Androgenic Alopecia (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Androgenic Alopecia (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Androgenic Alopecia (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Androgenic Alopecia (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Androgenic Alopecia (Dermatology)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Androgenic Alopecia (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Androgenic Alopecia (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aclaris Therapeutics Inc
  • Allergan Plc
  • Almirall SA
  • BiologicsMD Inc
  • Histogen Inc
  • Samumed LLC
  • MORE
Introduction

Androgenic Alopecia Overview

Therapeutics Development

Pipeline Products for Androgenic Alopecia - Overview

Androgenic Alopecia - Therapeutics under Development by Companies

Androgenic Alopecia - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Androgenic Alopecia - Products under Development by Companies

Androgenic Alopecia - Companies Involved in Therapeutics Development

Aclaris Therapeutics Inc

Allergan Plc

Almirall SA

BiologicsMD Inc

Dong-A Socio Holdings Co Ltd

Histogen Inc

RepliCel Life Sciences Inc

RiverTown Therapeutics Inc

Samumed LLC

Sucampo Pharmaceuticals Inc

SWITCH Biotech LLC

Androgenic Alopecia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(cyclosporine A + minoxidil + RT-175) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bimatoprost - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMD-1341 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BRM-421 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CB-0301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

finasteride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

finasteride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HGEN-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RCH-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RK-023 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

setipiprant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SM-04554 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Androgenic Alopecia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK for Alopecia Areata, Androgenetic Alopecia and Dermatological Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Androgenic Alopecia - Dormant Projects

Androgenic Alopecia - Discontinued Products

Androgenic Alopecia - Product Development Milestones

Featured News & Press Releases

Oct 25, 2016: Samumed Successfully Completes a Phase II Androgenetic Alopecia Biopsy Trial Studying Regeneration of Hair Follicles

Sep 26, 2016: RepliCel Provides Update on Shiseido License and Co-Development for RCH-01

Jul 21, 2016: RepliCel Cell Therapy for Pattern Baldness Proceeds to Clinical Trial Launch in Japan

Mar 07, 2016: Samumed Presents At The Annual Meeting Of The American Academy Of Dermatology Safety And Efficacy Results From Its Phase 2 Androgenetic Alopecia Trial

Feb 24, 2016: Cassiopea attains clinical endpoints in Breezula alopecia proof of concept trial

Dec 04, 2015: Samumed Announces Increases in Both Hair Count and Hair Density Observed in Its Phase II Study for a Potential Treatment of Androgenetic Alopecia

Nov 23, 2015: Samumed Completes Phase II Study for Its Potential Treatment of Androgenetic Alopecia: Safety Data Show No Serious Adverse Events in Any Treated Patient

Nov 18, 2015: Samumed to Announce Clinical Data on Potential Treatment of Androgenetic Alopecia at the World Congress for Hair Research

Dec 22, 2014: Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness

Oct 09, 2014: RepliCel to Present Commercial and Clinical Update at BioJapan 2014 World Business Forum

May 20, 2014: RepliCel Life Sciences' Licensing Partner, Shiseido, Opens Cell Processing and Expansion Facility in Japan to Advance RCH-01, a Treatment for Pattern Baldness

Feb 27, 2014: RepliCel to Present RCH-01 Phase 1 Clinical Data at the 13th Congress of the Japanese Society for Regenerative Medicine

Jan 13, 2014: RepliCel Receives Japanese Patent Covering its Hair Regeneration Technology

Dec 19, 2013: RepliCel Reports Progress on Shiseido Technology Transfer for RCH-01 Treatment for Pattern Baldness

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Androgenic Alopecia, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Androgenic Alopecia - Pipeline by Aclaris Therapeutics Inc, H2 2016

Androgenic Alopecia - Pipeline by Allergan Plc, H2 2016

Androgenic Alopecia - Pipeline by Almirall SA, H2 2016

Androgenic Alopecia - Pipeline by BiologicsMD Inc, H2 2016

Androgenic Alopecia - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016

Androgenic Alopecia - Pipeline by Histogen Inc, H2 2016

Androgenic Alopecia - Pipeline by RepliCel Life Sciences Inc, H2 2016

Androgenic Alopecia - Pipeline by RiverTown Therapeutics Inc, H2 2016

Androgenic Alopecia - Pipeline by Samumed LLC, H2 2016

Androgenic Alopecia - Pipeline by Sucampo Pharmaceuticals Inc, H2 2016

Androgenic Alopecia - Pipeline by SWITCH Biotech LLC, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Androgenic Alopecia - Dormant Projects, H2 2016

Androgenic Alopecia - Discontinued Products, H2 2016

List of Figures:

Number of Products under Development for Androgenic Alopecia, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 4
  • Aclaris Therapeutics Inc
  • Allergan Plc
  • Almirall SA
  • BiologicsMD Inc
  • Dong-A Socio Holdings Co Ltd
  • Histogen Inc
  • RepliCel Life Sciences Inc
  • RiverTown Therapeutics Inc
  • Samumed LLC
  • Sucampo Pharmaceuticals Inc
  • SWITCH Biotech LLC
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll